Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Endocrine
Published in: Endocrine 2/2019

Open Access 01-11-2019 | Pituitary Adenoma | Review

Treatment challenges in pediatric Cushing’s disease: Review of the literature with particular emphasis on predictive factors for the disease recurrence

Authors: Katarzyna Pasternak-Pietrzak, Elżbieta Moszczyńska, Mieczysław Szalecki

Published in: Endocrine | Issue 2/2019

Login to get access

Abstract

Cushing’s disease (CD) is a rare endocrine condition caused by a corticotroph pituitary tumor that produces adrenocorticotropic hormone. The current state of knowledge of CD treatment is presented in this article including factors that can be helpful in predicting remission and/or recurrence of the disease. The primary goals in CD treatment are quick diagnosis and effective, prompt treatment as the persistent disease is associated with increased morbidity and mortality. Cooperation of a team consisting of experienced pediatrician/adult endocrinologist, neuroradiologist, transsphenoidal neurosurgeon and (if necessary) radiotherapist contribute to the best treatment effects.
Literature
1.
2.
B.M. Biller, A.B. Grossman, P.M. Stewart, S. Melmed, X. Bertagna, J. Bertherat, Treatment of adrenocorticotropin-dependent Cushing’s syndrome: a consensus statement. Journal of Clinical Endocrinology and Metabolism 93, 2454–2462 (2008)PubMedCrossRefPubMedCentral
3.
L.K. Nieman, B.M. Biller, J.W. Findling, M.H. Murad, J. Newell-Price, M.O. Savage, Treatment of cushing’s syndrome: an endocrine society clinical practice guideline. Journal of Clinical Endocrinology and Metabolism 100(8), 2807–2831 (2015)PubMedCrossRefPubMedCentral
4.
M.C. Leinung, L.A. Kane, B.W. Scheithauer, P.C. Carpenter, E.R. Laws Jr., D. Zimmerman, Long term follow-up of transsphenoidal surgery for the treatment of Cushing’s disease in childhood. Journal of Clinical Endocrinology and Metabolism 80(8), 2475–2479 (1995)PubMed
5.
6.
7.
D.J. Devoe, W.L. Miller, F.A. Conte, S.L. Kaplan, M.M. Grumbach, S.M. Rosenthal et al. Long-term outcome in children and adolescents after transsphenoidal surgery for Cushing’s disease. Journal of Clinical Endocrinology and Metabolism 82(10), 3196–3202 (1997)PubMed
8.
9.
10.
H.L. Storr, P.N. Plowman, P.V. Carroll, I. Francois, G.E. Krassas, F. Afshar et al. Clinical and endocrine responses to pituitary radiotherapy in pediatric Cushing’s disease: an effective second-line treatment. Journal of Clinical Endocrinology and Metabolism 88, 34–37 (2003)PubMedCrossRef
11.
A.S. Kanter, A.O. Diallo, J.A. Jane Jr., J.P. Sheehan, A.R. Asthagiri, R.J. Oskouian et al. Single-center experience with pediatric Cushing’s disease. Journal of Neurosurgery 103, 413–420 (2005)PubMed
12.
13.
H.L. Storr, K.I. Alexandraki, L. Martin, A.M. Isidori, G.A. Kaltsas, J.P. Monson et al. Comparisons in the epidemiology, diagnostic features and cure rate by transsphenoidal surgery between paediatric and adult-onset Cushing’s disease. European Journal of Endocrinology 164(5), 667–74 (2011). https://​doi.​org/​10.​1530/​EJE-10-1120 CrossRefPubMed
14.
J. Hardy, Transphenoidal microsurgery of the normal and pathological pituitary. Clinical Neurosurgery 16, 185–217 (1969)PubMedCrossRef
15.
I. Ciric, S. Rosenblatt, J.C. Zhao, Transsphenoidal microsurgery. Neurosurgery 51(1), 161–169 (2002)PubMedCrossRef
16.
P. Cappabianca, L.M. Cavallo, A. Colao, E. de Divitiis, Surgical complications associated with the endoscopic endonasal transsphenoidal approach for pituitary adenomas. Journal of Neurosurgery 97, 293–8 (2002)PubMedCrossRef
17.
18.
19.
20.
M.A. Magiakou, G.P. Chrousos, Cushing’s syndrome in children and adolescents: current diagnostic and therapeutic strategies. Journal of Endocrinological Investigation 25(2), 181–94 (2002)PubMedCrossRef
21.
22.
23.
24.
25.
26.
M.A. Magiakou, G. Mastorakos, E.H. Oldfield, Cushing’s syndrome in children and adolescents, presentation, diagnosis and therapy. The New England Journal of Medicine 331, 629–636 (1994). 10.1056PubMedCrossRef
27.
28.
29.
30.
31.
32.
A.B. Atkinson, D.R. McCance, L. Kennedy, B. Sheridan, Cyclical Cushing’s syndrome first diagnosed after pituitary surgery: a trap for the unwary. Clinical Endocrinology 36(3), 297–299 (1992)PubMedCrossRef
33.
L.S. Blevins Jr., J.H. Christy, M. Khajavi, G.T. Tindall, Outcomes of therapy for Cushing’s disease due to adrenocorticotropin-secreting pituitary macroadenomas. Journal of Clinical Endocrinology and Metabolism 83, 63–67 (1998)PubMed
34.
35.
P.J. Trainer, H.S. Lawrie, J. Verhelst, T.A. Howlett, D.G. Lowe, A.B. Grossman et al. Transsphenoidal resection in Cushing’s disease: undetectable serum cortisol as the definition of successful treatment. Clinical Endocrinology 38, 73–78 (1993)PubMedCrossRef
36.
37.
38.
39.
C. Invitti, G. Redaelli, G. Baldi, F. Cavagnini, Glucocorticoid receptors in anorexia nervosa and Cushing’s disease. Biological Psychiatry 45(11), 1467–1471 (1999)PubMedCrossRef
40.
41.
G.H. Chee, D.B. Mathias, R.A. James, P. Kendall-Taylor, Transsphenoidal pituitary surgery in Cushing’s disease: can we predict outcome? Clinical Endocrinology 54(5), 617–26 (2001)PubMedCrossRef
42.
43.
D.R. McCance, D.S. Gordon, T.F. Fannin, D.R. Hadden, L. Kennedy., B. Sheridan et al. Assessment of endocrine function after transsphenoidal surgery for Cushing’s disease. Clinical Endocrinology 38, 79–86 (1993)PubMedCrossRef
44.
P.C. Avgerinos, G.P. Chrousos, L.K. Nieman, E.H. Oldfield, D.L. Loriaux, G.B. Cutler Jr., The corticotropin-releasing hormone test in the postoperative evaluation of patients with cushing’s syndrome. Journal of Clinical Endocrinology and Metabolism 65(5), 906–913 (1987)PubMedCrossRef
45.
46.
47.
48.
49.
M. Losa, P. Mortini, S. Dylgjeri, R. Barzaghi et al. Desmopressin stimulation test before and after pituitary surgery in patients with Cushing’s disease. Clinical Endocrinology 55(1), 61–8 (2001)PubMedCrossRef
50.
L. Barbetta, C. Dall’Asta, G. Tomei, M. Locatelli et al. Assessment of cure and recurrence after pituitary surgery for Cushing’s disease. Acta Neurochirurgica 143(5), 477–481 (2001)PubMedCrossRef
51.
52.
53.
N. Patronas, N. Bulakbasi, C.A. Stratakis, A. Lafferty, E.H. Oldfield, J. Doppman et al. Spoiled gradient recalled acquisition in the steady state technique is superior to conventional postcontrast spin echo technique for magnetic resonance imaging detection of adrenocorticotropin-secreting pituitary tumors. Journal of Clinical Endocrinology and Metabolism 88, 1565–1569 (2003)PubMedCrossRef
54.
D. Batista, N.A. Courkoutsakis, E.H. Oldfield et al. Detection of adrenocorticotropin-secreting pituitary adenomas by magnetic resonance imaging in children and adolescents with Cushing disease. Journal of Clinical Endocrinology and Metabolism 90, 5134–5140 (2005)PubMedCrossRef
55.
G.U. Mehta, B.K. Montgomery, P. Raghavan, S. Sharma, L.K. Nieman, N. Patronas et al. Different imaging characteristics of concurrent pituitary adenomas in a patient with Cushing’s disease. Journal of Clinical Neuroscience 22, 891–894 (2015)PubMedPubMedCentralCrossRef
56.
A.J. Dwyer, J.A. Frank, J.L. Doppman, E.H. Oldfield, A.M. Hickey, G.B. Cutler et al. Pituitary adenomas in patients with Cushing disease: initial experience with Gd-DTPA-enhanced MR imaging. Radiology 163, 421–426 (1987)PubMedCrossRef
57.
W. Kucharczyk, D.O. Davis, W.M. Kelly, G. Sze, D. Norman, T.H. Newton, Pituitary adenomas: high-resolution MR imaging at 1.5 T. Radiology 161, 761–765 (1986)PubMedCrossRef
58.
59.
Z. Feng, D. He, Z. Mao, Z. Wang, Y. Zhu, X. Zhang et al. Utility of 11C-methionine and 18F-FDG PET/CT in patients with functioning pituitary adenomas. Clinical Nuclear Medicine 41, 130–134 (2016)CrossRef
60.
61.
G.F. Pieters, A.R. Hermus, E. Meijer, A.G. Smals, P.W. Kloppenborg, Predictive factors for initial cure and relapse rate after pituitary surgery for Cushing’s disease. Journal of Clinical Endocrinology and Metabolism 69, 1122–1126 (1989)PubMedCrossRef
62.
63.
C. Invitti, F. Pecori Giraldi, M. De Martin, F. Cavagnini, Diagnosis and management of Cushing’s syndrome: results of an Italian multicentre study. Study Group of the Italian Society of Endocrinology on the Pathophysiology of the Hypothalamic-Pituitary-Adrenal Axis. Journal of Clinical Endocrinology and Metabolism 84, 440–448 (1999)PubMed
64.
F. Vignati, M.E. Berselli, P. Loi, Early postoperative evaluation in patients with Cushing’s disease: usefulness of ovine corticotropinreleasing hormone test in the prediction of recurrence of disease. European Journal of Endocrinology 130, 235–241 (1994)PubMedCrossRef
65.
66.
67.
F.R. Faucz, A. Tirosh, C. Tatsi, Somatic USP8 gene mutations are a common cause of pediatric cushing disease. Journal of Clinical Endocrinology and Metabolism 102(8), 2836–2843 (2017)PubMedCrossRefPubMedCentral
68.
69.
70.
Z. Ram, L.K. Nieman, G.B. Cutler Jr., Early repeat surgery for persistent Cushing’s disease. Journal of Neurosurgery 80(1), 37–45 (1994)PubMedCrossRef
71.
D. Zierhut, M. Flentje, J. Adolph, J. Erdmann, F. Raue, M. Wannenmacher, External radiotherapy of pituitary adenomas. International Journal of Radiation Oncology Biology Physics 33(2), 307–314 (1995)CrossRefPubMed
72.
73.
74.
A.S. Jennings, G.W. Liddle, D.N. Orth, Results of treating childhood Cushing’s disease with pituitary irradiation. New England Journal of Medicine 297, 957–962 (1977)PubMedCrossRef
75.
M. Thoren, T. Rahn, B. Hallengren, P.H. Kaad, K.O. Nilsson, H. Ravn et al. Treatment of Cushing’s disease in childhood and adolescence by stereotactic pituitary irradiation. Acta Paediatrica Scandinavica 75, 388–395 (1986)PubMedCrossRef
76.
77.
P.N. Plowman. Pituitary radiotherapy: techniques and potential complications. Clinical Endocrine Oncology. R. Sheaves, P.J. Jenkins, J.A. Wass (eds) Blackwell Scientific Publications, Oxford), 1997) 185–188
78.
P.N. Plowman, Pituitary adenoma radiotherapy-when, who and how? Clinical Endocrinology 51, 265–271 (1999)PubMedCrossRef
79.
J. Estrada, M. Boronat, M. Mielgo, R. Magallón, I. Millan, S. Díez et al. The long-term outcome of pituitary irradiation after unsuccessful transsphenoidal surgery in Cushing’s disease. New England Journal of Medicine 336(3), 172–177 (1997)PubMedCrossRef
80.
81.
82.
83.
M. Fuertes, J. Tkatch, J. Rosmino, L. Nieto, M.A. Guitelman, E. Artz, New insights in cushing disease treatment with focus on a derivative of vitamin A. Frontiers in Endocrinology 9, 262 (2018)PubMedPubMedCentralCrossRef
84.
85.
86.
87.
P. Igaz, Z. Tombol, P.M. Szabo, I. Liko, K. Racz, Steroid biosynthesis inhibitors in the therapy of hypercortisolism: Theory and practice. Current Medicinal Chemistry 15, 2734–2747 (2008)PubMedCrossRef
88.
J.E. Greening, Efficient short-term control of hypercortisolaemia by low-dose etomidate in severe paediatric Cushing’s disease. Hormone Research in Paediatrics 64(3), 140–143 (2005)CrossRef
89.
R. Pivonello, M.C. De Martino, P. Cappabianca, M. De Leo, A. Faggiano, G. Lombardi et al. The medical treatment of Cushing’s disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery. Journal of Clinical Endocrinology and Metabolism 94, 223–230 (2009). https://​doi.​org/​10.​1210/​jc.​2008-1533 CrossRefPubMed
90.
M. Boscaro, W.H. Ludlam, B. Atkinson, J.E. Glusman, S. Petersenn, M. Reincke et al. Treatment of pituitary-dependent Cushing’s disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial. Journal of Clinical Endocrinology and Metabolism 94, 115–122 (2009). https://​doi.​org/​10.​1210/​jc.​2008-1008 CrossRefPubMed
91.
92.
D.L. Batista, X. Zhang, R. Gejman, P.J. Ansell, Y. Zhou, S.A. Johnson, The effects of SOM230 on cell proliferation and adrenocorticotropin secretion in human corticotroph pituitary adenomas. Journal of Clinical Endocrinology and Metabolism 91, 4482–4488 (2006)PubMedCrossRef
93.
R. Pivonello, D. Ferone, W.W. de Herder, Dopamine receptor expression and function in corticotroph pituitary tumors. Journal of Clinical Endocrinology and Metabolism 89, 2452–2462 (2004)PubMedCrossRef
94.
95.
96.
A. Colao, S. Petersen, J. Newell-Price, J.W. Findling, F. Gu, M. Maldonado et al. A 12-month phase 3study of pasireotide in Cushing’s disease. New England Journal of Medicine 366, 914–924 (2012)PubMedCrossRef
97.
F. Ceccato, C. Scaroni, M. Boscaro, Clinical use of pasireotide for Cushing’s disease in adults. Therapeutics and Clinical Risk Management 11, 425–434 (2015)PubMedPubMedCentral
98.
M. Fleseriu, B.M. Biller, J.W. Findling, M.E. Molitch, D.E. Schteingart, C. Gross et al. Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing’s syndrome. Journal of Clinical Endocrinology and Metabolism 97(6), 2039–49 (2012). https://​doi.​org/​10.​1210/​jc.​2011-3350 CrossRefPubMed
99.
R.S. Newfield, I.M. Spitz, C. Isacson, M.I. New, Long-term mifepristone (RU486) therapy resulting in massive benign endometrial hyperplasia. Clinical Endocrinology 54, 399–404 (2001)PubMedCrossRef
100.
101.
102.
N.J. Hopwood, F.M. Kenny, Incidence of Nelson’s syndrome after adrenalectomy for Cushing’s disease in children: results of a nationwide survey. American Journal of Diseases of Children 131, 1353–1356 (1977)PubMedCrossRef
103.
C.G. Thomas, A.T. Smith, M. Benson, J. Griffith, Nelson’s syndrome after Cushing’s disease in childhood: a continuing problem. Surgery 96, 1067–1077 (1984)PubMed
104.
105.
T.M. Barber, E. Adams, O. Ansorge, J.V. Byrne, N. Karavitaki, J.A. Wass, Nelson’s syndrome. European Journal of Endocrinology 163(4), 495–507 (2010)PubMedCrossRef
106.
107.
M.O. Van Aken, A.M. Pereira, N.R. Biermasz, Quality of life in patients after long-term biochemical cure of Cushing’s disease. Journal of Clinical Endocrinology and Metabolism 90, 3279–3286 (2005)PubMedCrossRef
108.
109.
110.
M.A. Wagenmakers, R.T. Netea-Maier, J.B. Prins, T. Dekkers, M. den Heijer, A.R. Hermus et al. Impaired quality of life in patients in long-term remission of Cushing’s syndrome of both adrenal and pituitary origin: a remaining effect of long-standing hypercortisolism? European Journal of Endocrinology 167, 687–695 (2012). https://​doi.​org/​10.​1530/​EJE-12-0308 CrossRefPubMed
111.
M.F. Keil, D.P. Merke, R. Gandhi et al. Quality of life in children and adolescents 1-year after cure of Cushing syndrome: a prospective study. Clinical Endocrinology 71, 326–333 (2009)PubMedCrossRef
112.
F. Pecori Giraldi, M. Moro, F. Cavagnini; Study Group on the Hypothalamo-Pituitary-Adrenal Axis of the Italian Society of Endocrinology, Gender-related differences in the presentation and course of Cushing’s disease. Journal of Clinical Endocrinology and Metabolism 88(4), 1554–1558 (2003)PubMedCrossRef
113.
D.A. Rees, F.W. Hanna, J.S. Davies, R.G. Mills, J. Vafidis, M.F. Scanlon, Long-term follow-up results of transsphenoidal surgery for Cushing’s disease in a single centre using strict criteria for remission. Clinical Endocrinology 56(4), 541–551 (2002)PubMedCrossRef
114.
G. Rollin, N.P. Ferreira, M.A. Czepielewski, Prospective evaluation of transsphenoidal pituitary surgery in 108 patients with Cushing’s disease. Arquivos Brasileiros de Endocrinologia and Metabologia 51(8), 1355–1361 (2007)PubMedCrossRef
115.
116.
R. Valero, S. Vallette-Kasic, B. Conte-Devolx, P. Jaquet, T. Brue, The desmopressin test as a predictive factor of outcome after pituitary surgery for Cushing’s disease. European Journal of Endocrinology 151(6), 727–733 (2004)PubMedCrossRef
117.
S. Cannavò, B. Almoto, C. Dall’Asta, S. Corsello, R.M. Lovicu, E. De Menis et al. Long-term results of treatment in patients with ACTH-secreting pituitary macroadenomas. European Journal of Endocrinology 149(3), 195–200 (2003)PubMedCrossRef
118.
D. Bochicchio, M. Losa, M. Buchfelder, Factors influencing the immediate and late outcome of Cushing’s disease treated by transsphenoidal surgery: a retrospective study by the European Cushing’s Disease Survey Group. Journal of Clinical Endocrinology and Metabolism 80(11), 3114–3120 (1995)PubMed
119.
120.
121.
K. Hague, K.D. Post, S. Morgello, Absence of peritumoral Crooke’s change is associated with recurrence in surgically treated Cushing’s disease. Surgical Neurology 53(1), 77–81 (2000)PubMedCrossRef
Metadata
Title
Treatment challenges in pediatric Cushing’s disease: Review of the literature with particular emphasis on predictive factors for the disease recurrence
Authors
Katarzyna Pasternak-Pietrzak
Elżbieta Moszczyńska
Mieczysław Szalecki
Publication date
01-11-2019
Publisher
Springer US
Published in
Endocrine / Issue 2/2019
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-019-02036-2

Other articles of this Issue 2/2019

Endocrine 2/2019 Go to the issue

Review

A transgenic mouse that spontaneously develops pathogenic TSH receptor antibodies will facilitate study of antigen-specific immunotherapy for human Graves’ disease

Original Article

Thyroid nodules over 4 cm do not have higher malignancy or benign cytology false-negative rates

Original Article

Therapeutic sequences in patients with grade 1−2 neuroendocrine tumors (NET): an observational multicenter study from the ELIOS group

Original Article

Biomarkers of response to alpha-lipoic acid ± palmitoiletanolamide treatment in patients with diabetes and symptoms of peripheral neuropathy

Original Article

Ultrasound characterization for thyroid nodules with indeterminate cytology: inter-observer agreement and impact of combining pattern-based and scoring-based classifications in risk stratification

Original Article

Novel high molecular weight albumin-conjugated angiotensin II activates β-arrestin and G-protein pathways
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits